Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
January 2022 in “Yonsei Medical Journal” Spironolactone helps reduce fluid in the eye in Central Serous Chorioretinopathy, but doesn't improve vision and recurrence is common.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
December 2022 in “Indian Journal of Animal Research” Both fluoxetine and clomipramine effectively treat dog lick dermatitis, but fluoxetine works faster with lower recurrence, while clomipramine has fewer side effects.
A new treatment using conjugated linoleic acid in nanovesicles can rejuvenate hair follicles and improve hair growth in androgenic alopecia.
4350 citations
,
May 2012 in “Arthritis & Rheumatism” The new SLICC criteria for diagnosing lupus are more sensitive and accurate than the old criteria.
3 citations
,
March 2019 in “Journal of Pigmentary Disorders”
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
10 citations
,
April 2020 in “Dermatology and therapy” Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
44 citations
,
June 1985 in “Fertility and sterility” Combination drug therapy is effective for hirsutism that doesn't improve with just one medication.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
October 2025 in “Scholars Journal of Medical Case Reports” Intralesional corticosteroids effectively treat scalp Discoid Lupus and restore hair.
3 citations
,
October 2011 The updated criteria improve the accuracy of diagnosing lupus.
5 citations
,
July 2003 in “Annals of the Rheumatic Diseases” An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
October 2025 in “Journal of the Endocrine Society” Combining medication and minimally invasive techniques can effectively manage Marine-Lenhart syndrome.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
July 1988 in “Journal of The American Academy of Dermatology” Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” 1 citations
,
July 2025 in “Journal of Investigative Dermatology” 5 citations
,
May 2017 in “Journal of dermatological science” The combined treatment effectively managed severe skin issues in Olmsted syndrome.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.